Dateline – Mumbai, India, November 5, 2025:
Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635), a leading global pharmaceutical, health and wellness company, has announced its financial results for the second quarter (Q2) and half-year (H1) of FY26, showcasing resilience amid global funding uncertainties and an evolving regulatory landscape. While consolidated revenues stood at ₹2,044 crores in Q2FY26 and ₹3,977 crores for H1FY26, the company maintained strong quality compliance and strategic cost optimization despite market headwinds.
Science Significance
Piramal Pharma’s Contract Development and Manufacturing Organization (CDMO) segment continues to underscore its scientific depth with a focus on differentiated capabilities such as Antibody Drug Conjugates (ADC), sterile fill-finish, and on-patent commercial manufacturing. The company also made significant progress with a multi-million-dollar collaboration with NewAmsterdam Pharma for manufacturing Obicetrapib and Ezetimibe, highlighting its commitment to scientific innovation and technology-driven scalability in drug manufacturing
Regulatory Significance
Maintaining its “Zero OAI” (Official Action Indicated) status, Piramal successfully closed 19 regulatory inspections, including one USFDA inspection with zero observations in H1FY26 — a notable benchmark for global cGMP and cGxP excellence. Additionally, the company’s efforts to secure ex-US market approvals for its Digwal plant reflect its proactive alignment with international regulatory harmonization and export readiness.
Business Significance
Advertisement
Despite a 9% YoY decline in Q2 revenue, primarily due to inventory destocking and slower biopharma funding, Piramal mitigated impact through cost optimization and operational excellence. EBITDA for H1FY26 stood at ₹389 crores, while net debt was reduced by ₹228 crores, strengthening financial stability. The Complex Hospital Generics (CHG) business retained a 45% U.S. market share in Sevoflurane, with expansion plans into ex-US territories, while the Piramal Consumer Healthcare (PCH) division achieved 20% YoY growth led by power brands like Lacto Calamine and Little’s.
Patients’ Significance
Piramal’s robust portfolio of hospital generics, inhalation anesthetics, and intrathecal therapies ensures continuity of care and affordability for critical care patients worldwide. The company’s 75% U.S. market share in intrathecal Baclofen and expanding access to high-quality generics reinforce its mission to provide safe, effective, and accessible healthcare solutions for patients with complex medical needs.
Policy Significance
By releasing its 4th Annual Sustainability Report – “Innovating Responsibly. Growing Sustainably”, Piramal Pharma demonstrates alignment with India’s ESG and sustainability goals. The report, verified by DNV Business Assurance, highlights measurable progress across four strategic pillars, showcasing the company’s integration of environmental, social, and governance principles within a regulated pharmaceutical framework — a model for policy-aligned growth under India’s evolving pharma leadership vision.
Nandini Piramal, Chairperson of Piramal Pharma Limited, emphasized that while macroeconomic pressures and funding slowdowns affected short-term growth, biopharma recovery in late 2025 and strong RFP inflows signal renewed momentum ahead. With sustained focus on scientific innovation, regulatory excellence, patient impact, and sustainable business operations, Piramal Pharma continues to solidify its position as a trusted global partner in drug development, manufacturing, and patient wellness.
Source: Piramal Pharma Limited press release
